Home / Science / Psychedelics Combat Inflammation in Parkinson's Patients
Psychedelics Combat Inflammation in Parkinson's Patients
21 Oct
Summary
- Psilocybin significantly reduced inflammation markers in Parkinson's patients.
- The study observed improvements in cellular energy production.
- Findings suggest broader applications for inflammatory and neuropsychiatric disorders.
New research suggests that classic psychedelics, such as psilocybin, may hold therapeutic potential for diseases characterized by inflammation and immune dysregulation throughout the body, not just within the brain. A pilot study involving 12 patients with Parkinson's disease, published in JAMA Psychiatry, provided early human evidence for this effect.
Participants in the study showed significantly reduced levels of five different inflammation signaling molecules after two psilocybin sessions. These anti-inflammatory effects persisted for a month after treatment. Additionally, a marker for mitochondrial stress, crucial for cellular energy production, improved immediately following psilocybin administration, though this longer-term effect was not sustained.
The research, conducted at the University of California, San Francisco, also highlighted a promising safety profile for psilocybin in Parkinson's patients, who are typically excluded from psychedelic trials. While the study lacked a control group, the observed objective biological changes are considered a strong indicator for further investigation.
These findings extend previous lab and animal studies demonstrating psychedelics' anti-inflammatory and mitochondrial protective properties. Researchers believe this opens new avenues for exploring psychedelics not only for Parkinson's but also for a broader spectrum of conditions, including depression, anxiety, and other cardio-metabolic and inflammatory disorders.
